

S3 Table. Second-line chemotherapy in patients with progressive disease during or after THP treatment

Second-line treatment	No. (%) (n=126)
Trastuzumab emtansine	91 (72.2)
Lapatinib/Capecitabine	22 (17.4)
Cytotoxic chemotherapy (anthracyclines/cyclophosphamides)	8 (6.3)
Other	5 (3.9)

THP, docetaxel, trastuzumab, pertuzumab.